{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Age-Related+Macular+Degeneration+%28ARMD%29&page=25",
    "query": {
      "condition": "Age-Related Macular Degeneration (ARMD)",
      "page": 25
    },
    "page_size": 10
  },
  "pagination": {
    "page": 25,
    "page_size": 10,
    "total_count": 909,
    "total_pages": 91,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Age-Related+Macular+Degeneration+%28ARMD%29&page=26&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Age-Related+Macular+Degeneration+%28ARMD%29&page=24&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-16T13:25:34.292Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01485588",
      "title": "Safety and Tolerability Study for Age-Related Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Neovascular Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "hI-con1™ 60µl",
          "type": "DRUG"
        },
        {
          "name": "hI-con1™ 150µl",
          "type": "DRUG"
        },
        {
          "name": "hI-con1™ 300µl",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Iconic Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2010-12",
      "completion_date": "2012-03",
      "has_results": true,
      "last_update_posted_date": "2020-11-06",
      "last_synced_at": "2026-10-16T13:25:34.292Z",
      "location_count": 5,
      "location_summary": "Missoula, Montana • Ashland, Oregon • West Columbia, South Carolina + 2 more",
      "locations": [
        {
          "city": "Missoula",
          "state": "Montana"
        },
        {
          "city": "Ashland",
          "state": "Oregon"
        },
        {
          "city": "West Columbia",
          "state": "South Carolina"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "McAllen",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01485588"
    },
    {
      "nct_id": "NCT01857544",
      "title": "Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Retinal Vein Occlusion"
      ],
      "interventions": [
        {
          "name": "Aflibercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tennessee Retina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2013-06",
      "completion_date": "2016-03",
      "has_results": false,
      "last_update_posted_date": "2014-10-29",
      "last_synced_at": "2026-10-16T13:25:34.292Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01857544"
    },
    {
      "nct_id": "NCT00964795",
      "title": "Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular (\"Wet\") Age-related Macular Degeneration (AMD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neovascular Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Intravitreal Aflibercept Injection 2mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 323,
      "start_date": "2009-12",
      "completion_date": "2013-08",
      "has_results": true,
      "last_update_posted_date": "2015-03-23",
      "last_synced_at": "2026-10-16T13:25:34.292Z",
      "location_count": 115,
      "location_summary": "Birmingham (2 Locations), Alabama • Phoenix (2 Locations), Arizona • Tucson (2 Locations), Arizona + 112 more",
      "locations": [
        {
          "city": "Birmingham (2 Locations)",
          "state": "Alabama"
        },
        {
          "city": "Phoenix (2 Locations)",
          "state": "Arizona"
        },
        {
          "city": "Tucson (2 Locations)",
          "state": "Arizona"
        },
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00964795"
    },
    {
      "nct_id": "NCT07419334",
      "title": "Study of ALK-001 on the Progression of Stargardt Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Stargardt Disease"
      ],
      "interventions": [
        {
          "name": "ALK-001",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alkeus Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "8 Years to 45 Years"
      },
      "enrollment_count": 230,
      "start_date": "2026-06-03",
      "completion_date": "2030-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-18",
      "last_synced_at": "2026-10-16T13:25:34.292Z",
      "location_count": 14,
      "location_summary": "Phoenix, Arizona • Aurora, Colorado • Gainesville, Florida + 11 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07419334"
    },
    {
      "nct_id": "NCT06550011",
      "title": "Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Neovascular (Wet) AMD"
      ],
      "interventions": [
        {
          "name": "ABI-110 Low Dose",
          "type": "DRUG"
        },
        {
          "name": "ABI-110 Medium Dose",
          "type": "DRUG"
        },
        {
          "name": "ABI-110 High Dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Avirmax Biopharma Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "50 Years to 89 Years"
      },
      "enrollment_count": 18,
      "start_date": "2024-08-07",
      "completion_date": "2031-01-16",
      "has_results": false,
      "last_update_posted_date": "2026-02-12",
      "last_synced_at": "2026-10-16T13:25:34.292Z",
      "location_count": 4,
      "location_summary": "Bakersfield, California • Walnut Creek, California • San Antonio, Texas + 1 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "The Woodlands",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06550011"
    },
    {
      "nct_id": "NCT07496567",
      "title": "A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Macular Degeneration",
        "Age-Related Macular Degeneration",
        "Choroidal Neovascularization",
        "Wet Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Tiespectus",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EyeBiotech Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 960,
      "start_date": "2026-04-15",
      "completion_date": "2028-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-06",
      "last_synced_at": "2026-10-16T13:25:34.292Z",
      "location_count": 52,
      "location_summary": "Gilbert, Arizona • Encino, California • Mountain View, California + 49 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Mountain View",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07496567"
    },
    {
      "nct_id": "NCT01231633",
      "title": "Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Macular Edema",
        "Central Retinal Vein Occlusion"
      ],
      "interventions": [
        {
          "name": "Ozurdex",
          "type": "DRUG"
        },
        {
          "name": "Avastin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Long Island Vitreoretinal Consultants",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2010-09",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2018-04-03",
      "last_synced_at": "2026-10-16T13:25:34.292Z",
      "location_count": 4,
      "location_summary": "Toms River, New Jersey • Great Neck, New York • Hauppauge, New York + 1 more",
      "locations": [
        {
          "city": "Toms River",
          "state": "New Jersey"
        },
        {
          "city": "Great Neck",
          "state": "New York"
        },
        {
          "city": "Hauppauge",
          "state": "New York"
        },
        {
          "city": "Riverhead",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01231633"
    },
    {
      "nct_id": "NCT07439887",
      "title": "Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Stargardt Disease"
      ],
      "interventions": [
        {
          "name": "RTx-021",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Ray Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2026-01-28",
      "completion_date": "2030-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-15",
      "last_synced_at": "2026-10-16T13:25:34.292Z",
      "location_count": 3,
      "location_summary": "Bakersfield, California • Pittsburgh, Pennsylvania • Bellaire, Texas",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Bellaire",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07439887"
    },
    {
      "nct_id": "NCT03748784",
      "title": "ADVM-022 Intravitreal Gene Therapy for Wet AMD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Wet Age-related Macular Degeneration",
        "Neovascular Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "ADVM-022",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Adverum Biotechnologies, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2018-11-14",
      "completion_date": "2022-06-22",
      "has_results": false,
      "last_update_posted_date": "2023-08-08",
      "last_synced_at": "2026-10-16T13:25:34.292Z",
      "location_count": 11,
      "location_summary": "Bakersfield, California • Beverly Hills, California • Golden, Colorado + 8 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Golden",
          "state": "Colorado"
        },
        {
          "city": "Deerfield Beach",
          "state": "Florida"
        },
        {
          "city": "Reno",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03748784"
    },
    {
      "nct_id": "NCT03525613",
      "title": "A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Geographic Atrophy"
      ],
      "interventions": [
        {
          "name": "APL-2",
          "type": "DRUG"
        },
        {
          "name": "Sham Procedure",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Apellis Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 637,
      "start_date": "2018-08-31",
      "completion_date": "2022-06-28",
      "has_results": true,
      "last_update_posted_date": "2023-07-06",
      "last_synced_at": "2026-10-16T13:25:34.292Z",
      "location_count": 67,
      "location_summary": "Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 56 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Campbell",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03525613"
    }
  ]
}